Innovating Works

OI LJUBLJANA

Desconocido
ZAP Cancer: TWINNING FOR EXCELLENCE TO ADVANCE RESEARCH IN THE ACTIVATION OF ANTI-TUMOR IMMUNE RESPONSE AFTER EL... ONKOLOSKI INSTITUT LJUBLJANA tramitó un HORIZON EUROPE: HORIZON-WIDERA-2023-ACCESS-02 More than a decade has passed since the first immune checkpoint inhibitor (ICI) was approved for the treatment of advanced melanoma, marking...
2024-10-01 - 2027-09-30 | Financiado
RadExIORSBoost: Twinning to skyrocket scientific excellence towards individual radiosensitivity prediction by raisin... ONKOLOSKI INSTITUT LJUBLJANA participó en un HORIZON EUROPE: HORIZON-WIDERA-2023-ACCESS-02 Prostate cancer patients receiving radiotherapy (RT) may develop radiation-induced side effects, which significantly impact quality of life....
2024-05-22 - 2027-09-30 | Financiado
e-QuoL: e health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patien... ONKOLOSKI INSTITUT LJUBLJANA participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the int...
2023-12-13 - 2027-12-31 | Financiado
PARC: Partnership for the Assessment of Risks from Chemicals ONKOLOSKI INSTITUT LJUBLJANA participó en un HORIZON EUROPE: HORIZON-HLTH-2021-ENVHLTH-03 PARC is an EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bod...
2022-05-24 - 2029-04-30 | Financiado
EU-TOPIA-EAST: TOwards imProved screening for breast cervical and colorectal cancer in Eastern Europe Equitable... ONKOLOSKI INSTITUT LJUBLJANA participó en un H2020: H2020-SC1-BHC-2018-2020 Colorectal, breast and cervical cancer cause 155,000 deaths each year in middle income countries (MIC) in Eastern Europe, while there is goo...
2021-02-04 - 2026-04-30 | Financiado
CARDIOCARE: AN INTERDISCIPLINARY APPROACH FOR THE MANAGEMENT OF THE ELDERLY MULTIMORBID PATIENT WITH BREAST CANC... ONKOLOSKI INSTITUT LJUBLJANA participó en un H2020: H2020-SC1-BHC-2018-2020 More than 50% of the newly diagnosed breast cancer patients are elderly and particularly susceptible to cardiotoxicity of cancer treatment d...
2021-01-22 - 2025-06-30 | Financiado
EU-TOPIA: EU TOPIA TOWARDS IMPROVED SCREENING FOR BREAST CERVICAL AND COLORECTAL CANCER IN ALL OF EUROPE ONKOLOSKI INSTITUT LJUBLJANA participó en un H2020: H2020-PHC-2014-2015 Breast, colorectal and cervical cancer cause 250,000 deaths each year, representing 20% of EU-cancer mortality. Although important progress...
2015-04-13 - 2020-08-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.